



- A Compassionate Access Program (CAP) approval must be granted prior to proceeding with Oncotype DX® testing.
- Clinicians must submit a CAP application, a signed patient consent form and a Genomic Health (GHI) requisition form to the CAP office for approval.
- The CAP program will requisition the test directly with GHI, and GHI will then connect with the appropriate laboratory to obtain the required tissue specimens. (CAP sends both the consent form and the GHI requisition)
- Testing not requisitioned through the CAP program will not be funded by the BCCA. For CAP requests that have been denied, clinicians will be notified and the patient consent form will be shredded for confidentiality purposes.
- Appeals can be done through the normal CAP appeal process as outlined in the BCCA Compassionate Access Program (CAP) Policy (III-45).